Alterations in inflammatory biomarkers and energy intake in cancer cachexia: a prospective study in patients with inoperable pancreatic cancer
| Autor: | Marianne Jensen Hjermstad, Grete S Skjegstad, Kirsten B. Holven, Asta Bye, Stine Marie Ulven, Per Ole Iversen, Nima Wesseltoft-Rao |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male Cancer Research medicine.medical_specialty Pathology Cachexia Pilot Projects Adenocarcinoma Gastroenterology 03 medical and health sciences 0302 clinical medicine Adipokines Weight loss Internal medicine Pancreatic cancer medicine Biomarkers Tumor Humans Longitudinal Studies Prospective Studies Prospective cohort study Aged Neoplasm Staging Inflammation Hematology business.industry Case-control study General Medicine Middle Aged medicine.disease Pancreatic Neoplasms 030104 developmental biology Oncology 030220 oncology & carcinogenesis Sarcopenia Case-Control Studies Cytokines Female medicine.symptom business Energy Intake |
| Zdroj: | Medical Oncology |
| Popis: | Chronic systemic inflammatory response is proposed as an underlying mechanism for development of cancer cachexia. We conducted a prospective study to examine changes in inflammatory biomarkers during the disease course and the relationship between inflammatory biomarkers and cachexia in patients with inoperable pancreatic cancer. Twenty patients, median (range) age 67.5 (35–79) years, 5 females, were followed for median 5.5 (1–12) months. Cachexia was diagnosed according to the 2011 consensus-based classification system (weight loss >5 % past six months, BMI < 20 kg/m2 and weight loss >2 %, or sarcopenia) and the modified Glasgow Prognostic score (mGPS) that combines CRP and albumin levels. Inflammatory biomarkers were measured by enzyme immunoassays. The patients had increased levels of most inflammatory biomarkers, albeit not all statistically significant, both at study entry and close to death, indicating ongoing inflammation. According to the consensus-based classification system, eleven (55 %) patients were classified as cachectic upon inclusion. They did not differ from non-cachectic patients with regard to inflammatory biomarkers or energy intake. According to the mGPS, seven (35 %) were defined as cachectic and had a higher IL-6 (p < 0.001) than the non-cachectic patients. They also had a slightly, but insignificantly longer survival than non-cachectic patients (p = 0.08). The mGPS should be considered as an additional framework for identification of cancer cachexia. © Springer-Verlag 2016. The final publication isavailable at https://link.springer.com/article/10.1007%2Fs12032-016-0768-2 . This is the authors' accepted and refereed manuscript to the article. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|